Ascendis Pharma Company Description

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally.

The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism.

It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

The company was incorporated in 2006 and is based in Hellerup, Denmark.

Ascendis Pharma A/S

Country	Denmark
Founded	2006
Industry	Biotechnology
Sector	Healthcare
Employees	1,017
CEO	Jan Mikkelsen

Contact Details

Address: Tuborg Boulevard 12 Hellerup, 2900 Denmark
Phone	45 70 22 22 44
Website	ascendispharma.com

Stock Details

Ticker Symbol	A1SN34
Exchange	Brazil Stock Exchange
Fiscal Year	January - December
Reporting Currency	EUR
SIC Code	2836

Key Executives

Name	Position
Jan Moller Mikkelsen	President, Chief Executive Officer, Member of Executive Board and Executive Director
Scott T. Smith	Chief Financial Officer, Executive Vice President and Member of Executive Board
Pedersen Anni Lotte Kirstine Sonderbjerg	Executive Vice President, Chief Administrative Officer and Member of the Executive Board
Michael Wolff Jensen L.L.M.	Executive Vice President, Chief Legal Officer and Member of the Executive Board
Mads Bodenhoff	Senior Vice President, Head of Finance and Principal Accounting Officer
Flemming Steen Jensen	Executive Vice President of Product Supply and Quality
Dr. Kennett Sprogoe Ph.D.	Executive Vice President and Head of Research and Product Development
Dr. Stina Singel M.D., Ph.D.	Executive Vice President and Head of Clinical Development for Oncology
Joseph Kelly	Head of U.S. Commercial of Endocrinology
Sherrie Glass	Chief Business Officer